Armenia vs Russian Federation: Average cost of multi drug-resistant tuberculosis treatment
Armenia
2,970 constant 2022 US$
in 2024
Russian Federation
2,751 constant 2022 US$
in 2024
Armenia rank
16th
Russian Federation rank
18th
Average cost of multi drug-resistant tuberculosis treatment over time
- Armenia
- Russian Federation
How they compare
Armenia currently reports 2,970 constant 2022 US$ against 2,751 constant 2022 US$ in Russian Federation, a difference of 219 constant 2022 US$.
That makes Armenia's figure about 1.1 times Russian Federation's.
Across all 5 years both countries report, Armenia has been ahead every year.
Armenia ranks 16th and Russian Federation ranks 18th of 92 countries.
Armenia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Armenia | Russian Federation | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,850 constant 2022 US$ | 2,327 constant 2022 US$ | 2,523 constant 2022 US$ | Armenia |
| 2020s | 4,038 constant 2022 US$ | 2,819 constant 2022 US$ | 1,219 constant 2022 US$ | Armenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Armenia or Russian Federation?
- Armenia, at 2,970 constant 2022 US$ against 2,751 constant 2022 US$ in Russian Federation as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Armenia and Russian Federation?
- 219 constant 2022 US$, with Armenia ahead.
- How many years of comparable data are there for Armenia and Russian Federation?
- 5 years are reported by both, from 2019 to 2024.
- How do Armenia and Russian Federation rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Armenia ranks 16th and Russian Federation ranks 18th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.